ArticleCancer gene therapy2025
Bacillus Calmette-Guerin induces CD8+ T cell infiltration and suppresses tumor progression in microsatellite stable colorectal cancer by downregulating ARID1A.
Article in Cancer gene therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The TRIM-cancer paradox: BCG as a programmable vaccine platform and a mechanistic probe for rational immunotherapy design.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Neoadjuvant immunotherapy demonstrates limited efficacy in microsatellite-stable (MSS) colorectal cancer (CRC). In vivo observations reveal that Bacillus Calmette-Guérin (BCG) can inhibit the progression of MSS-CRC and downregulate ARID1A in both in vivo and in vitro settings. Through the analysis of clinical samples, in vivo and in vitro models, and bioinformatics, we found that the low expression of ARID1A promotes tumor growth in vitro; however, in vivo, it enhances CD8+ T cell infiltration in MSS-CRC tissues while inhibiting tumor growth. Further investigation revealed that BCG downregulates ARID1A via the TLR4/NF-κB pathway, leading to the downregulation of MLH1 and PMS2 and subsequent alterations in MMR function in MSS-CRC. This cascade enhances antigen presentation, promotes CD8+ T cell infiltration, and contributes to tumor suppression.
Indexed as
Identifiers
40975712What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.